Document:

Exhibit 10.4

 

EXECUTION VERSION

 

 

REGISTRATION
RIGHTS AGREEMENT

This Registration Rights Agreement (this
“Agreement”) is dated as of May 21, 2013, among GUIDED THERAPEUTICS, INC., a Delaware corporation (the “Company”),
and the entities listed on the signature pages hereto (each, a “Purchaser” and, collectively, the “Purchasers”).

In connection with that certain Securities
Purchase Agreement among the parties hereto dated the date hereof (the “Securities Purchase Agreement”), the
Company has agreed, upon the terms and subject to the conditions set forth in the Securities Purchase Agreement, to issue and sell
to the Purchasers listed on the signature pages hereof an aggregate of up to 3,000 shares of the Company’s Series B
Convertible Preferred Stock, par value $.001 per share (the “Preferred Stock”), which will be mandatorily convertible
into shares of the Company’s common stock, par value $.001 per share (the “Common Stock”), subject to
and in accordance with the terms and conditions of the Certificate of Designation setting forth the terms of the Preferred Stock
(the shares of Common Stock issuable upon such conversion, including any shares of Common Stock paid as dividends on the Preferred
Stock pursuant to the terms thereof, the “Conversion Shares”) and warrants (the “Warrants”),
exercisable according to their terms to purchase an aggregate of approximately 4,411,765 shares of Common Stock (as exercised,
collectively, the “Warrant Shares”).

In accordance with the terms of the Securities
Purchase Agreement, the Company has agreed to provide to the Purchasers certain registration rights under the Securities Act of
1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “Securities
Act”), and applicable state securities laws. The execution and delivery of this Agreement is a condition to the Purchasers’
obligations under the Securities Purchase Agreement.

Therefore, the Company and the Purchasers
agree as follows:

1.             
Definitions.

Capitalized terms used herein and not
otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement. As used in this Agreement,
the following terms shall have the respective meanings set forth in this Section 1:

“Additional Payment Amount”
shall have the meaning set forth in Section 2(d).

“Advice” shall have
the meaning set forth in Section 2(e).

“Business Day” means
(i) a day on which the Common Stock is traded on a Trading Market, (ii) if the Common Stock is not listed on any Trading
Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by the Pink OTC Markets Inc. (or any
similar organization or agency succeeding to its functions of reporting prices) or (iii) in the event that the Common Stock
is not listed or quoted as set forth in (i) and (ii) hereof, any day other than a Saturday, a Sunday or a day on which banking
institutions in New York City are authorized or required by law, regulation or executive order to remain closed.

“Closing Price” shall
mean, per share of Common Stock on any date specified herein, (a) the last sale price on such date of such Common Stock or,
if no such sale takes place on such date, the average of the closing bid and asked prices thereof on such date, in each case as
officially reported on the principal national securities exchange on which such Common Stock is then listed or admitted to trading,
or (b) if such Common Stock is not then listed or admitted to trading on any national securities exchange but is trading on the
over-the-counter market, the last sale price as reported by OTC Markets Group, Inc., or (c) if neither (a) nor (b) is applicable,
a price per share thereof equal to the fair value thereof determined in good faith by a resolution of the Board of Directors of
the Company as of a date which is within 15 days of the date as of which the determination is to be made.

“Commission” means
the U.S. Securities and Exchange Commission.

“Common Stock” shall
have the meaning set forth in the preamble.

“Company” shall have
the meaning set forth in the preamble.

“Conversion Shares”
shall have the meaning set forth in the preamble.

“Effective Date” means,
with respect to any Registration Statement, the date that the Commission first declares effective such Registration Statement.

“Effectiveness Deadline”
means an Initial Effectiveness Deadline or a Subsequent Effectiveness Deadline.

“Effectiveness Period”
shall have the meaning set forth in Section 2(a).

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Filing Deadline”
means (a) with respect to the initial Registration Statement to be filed pursuant to Section 2(a), the 45th day
following the Closing Date under the Securities Purchase Agreement, and (b) with respect to any additional Registration Statement
to be filed pursuant to Section 2(b), the 45th day following the date that the Commission shall indicate as being
the first date or time that such filing may be made.

“Holder” or “Holders”
means the holder or holders, as the case may be, from time to time of Registrable Securities.

“Indemnified Party”
shall have the meaning set forth in Section 5(c).

“Indemnifying Party”
shall have the meaning set forth in Section 5(c).

“Initial Effectiveness Deadline”
means, with respect to the Registration Statement filed pursuant to Section 2(a), the date that is (a) in the
event that the Registration Statement is not subjected to a full review by the Commission, 75 days after the Closing Date
under the Securities Purchase Agreement or (b) in the event that the Registration Statement is subjected to a full review
by the Commission, 120 days after the Closing Date under the Securities Purchase Agreement.

“Losses” shall have
the meaning set forth in Section 5(a).

“Proceeding” means
an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or threatened.

“Prospectus” means
the prospectus included in a Registration Statement (including, without limitation, any preliminary prospectus, any free-writing
prospectus and any prospectus that includes any information previously omitted from a prospectus filed as part of an effective
registration statement under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the
terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments
and supplements to such prospectus, including post-effective amendments, and all material incorporated by reference or deemed to
be incorporated by reference in such prospectus.

“Purchaser” shall
have the meaning set forth in the preamble.

“Registrable Securities”
means each of the Conversion Shares and the Warrant Shares upon original issuance and at all times subsequent thereto until (i) a
Registration Statement covering such Security has been declared effective by the Commission and such Security has been disposed
of in accordance with such effective Registration Statement; (ii) such Security ceases to be outstanding; or (iii) such
Security has been sold in compliance with Rule 144 or is salable pursuant to Rule 144(d) (or any similar provision then
in force other than Rule 144A).

“Registration Default”
shall have the meaning set forth in Section 2(d).

“Registration Statement”
means a registration statement filed pursuant to the terms hereof and which covers the resale by the Holders of Registrable Securities,
including the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto and all material incorporated by reference (or deemed to be incorporated by reference) therein.
For the avoidance of doubt, “Registration Statement” means the initial registration statement described above in this
paragraph and any additional registration statement or registration statements that are needed to sell additional Registrable Securities
with the effect that the obligations of the Company under this Agreement also extend to such additional registration statement
or registration statements, in all cases, as specified in this Agreement.

“Rule 144” means
Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any
similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

“Rule 415” means
Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any
similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

“Rule 424” means Rule 424
promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule
or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

“Securities” means
the Conversion Shares issued pursuant to the Securities Purchase Agreement, together with any Warrant Shares and any other securities
issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event or conversion price
adjustment with respect thereto.

“Securities Act” shall
have the meaning set forth in the preamble.

“Securities Purchase Agreement”
shall have the meaning set forth in the preamble.

“Selling Holder Questionnaire”
shall have the meaning set forth in Section 2(e).

“Subsequent Effectiveness Deadline”
means, with respect to any additional Registration Statement filed pursuant to Section 2(b), the date that is (a) in
the event that the Registration Statement is not subject to a full review by the Commission, 45 days after the Filing Deadline
applicable to such Registration Statement, or (b) in the event that the Registration Statement is subject to a full review
by the Commission, 75 days after the Filing Deadline applicable to such Registration Statement.

“Subsequent Form S-3”
shall have the meaning set forth in Section 3(g).

“Suspension Period”
shall have the meaning set forth in Section 2(c).

“Trading Market” means
whichever of the New York Stock Exchange, the American Stock Exchange, the Nasdaq Global Market, the Nasdaq Capital Market
or such other United States registered national securities exchange on which the Common Stock is listed or quoted for trading on
the date in question.

“Warrants” shall have
the meaning set forth in the preamble.

“Warrant Shares” shall
have the meaning set forth in the preamble.

2.             
Registration.

(a)               
Initial Registration. On or prior to the Filing Deadline, the Company shall prepare and file with the Commission
a Registration Statement covering the resale of all Registrable Securities for an offering to be made on a continuous basis pursuant
to Rule 415. The Registration Statement shall be on Form S-1 or S-3 (except if the Company is not then eligible to register
for resale the Registrable Securities on Form S-1 or S-3, in which case such registration shall be on another appropriate
form for such purpose) and shall contain (except if otherwise required pursuant to written comments received from the Commission
upon a review of such Registration Statement) a “Plan of Distribution” substantially in the form attached hereto as
Annex A, as the same may be amended in accordance with the provisions of this Agreement. The Company shall use its
commercially reasonable efforts to cause the Registration Statement to be declared effective under the Securities Act as soon as
possible but, in any event, no later than the Initial Effectiveness Deadline, and shall use its commercially reasonable efforts
to keep the Registration Statement (or a Subsequent Form S-3, as defined below) continuously effective under the Securities
Act until the second year after the Effective Date or such earlier date when all Registrable Securities covered by the Registration
Statement cease to be Registrable Securities as determined by the counsel to the Company (the “Effectiveness Period”).
Until the Effective Date, the Company shall not file any other registration statements to register the issuance by the Company
of any securities, other than registration statements on Form S-8.

(b)              
Subsequent Registrations. If for any reason the Commission does not permit all of the Registrable Securities to be
included in the Registration Statement initially filed pursuant to Section 2(a), then the Company shall prepare and
file as soon as possible after the date on which the Commission shall indicate as being the first date or time that such filing
may be made, but in any event by the Filing Deadline, an additional Registration Statement covering the resale of all Registrable
Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis
pursuant to Rule 415. The Company shall use its commercially reasonable efforts to cause such Registration Statement to be
declared effective under the Securities Act as soon as possible but, in any event, no later than the Subsequent Effectiveness Deadline,
and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities
Act during the Effectiveness Period.

(c)               
Suspension Periods. Notwithstanding anything to the contrary contained herein, the Company may suspend the effectiveness
of a Registration Statement by written notice to the Holders for a period (each such period, a “Suspension Period”)
not to exceed an aggregate of 30 days in any 90-day period, and not to exceed an aggregate of 60 days in any 360-day
period, if:

		(i)	an event occurs and is continuing as a result of which, if such event were not disclosed in the Registration Statement, the
Registration Statement would, in the Company’s reasonable judgment, contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading; and

		(ii)	the Company reasonably determines in good faith that the disclosure of such event at such time would be materially detrimental
to the Company or its business;

provided that, in the event the disclosure relates to a previously
undisclosed proposed or pending material business transaction, the disclosure of which would impede the Company’s ability
to consummate such transaction, the Company may extend a Suspension Period from 30 days to 45 days during any 90-day
period.

(d)              
Additional Payment Amounts. The Company and the Purchasers agree that the Holders will suffer damages if the Company
fails to fulfill its obligations under this Section 2 and that it would not be feasible to ascertain the extent of
such damages with precision. Accordingly, if:

		(i)	a Registration Statement is not filed with the Commission on or before the applicable Filing Deadline;

		(ii)	a Registration Statement is not declared effective by the Commission on or before the applicable Effectiveness Deadline;

		(iii)	a Registration Statement is filed and declared effective but, during the applicable Effectiveness Period, shall cease to be
effective, including by reason of its withdrawal or termination pursuant to Section 3(g), or, other than by reason
of a Suspension Period as provided in Section 2(c), shall fail to be usable for its intended purpose without such disability
being cured within ten Business Days by an effective post-effective amendment to such Registration Statement, a supplement to the
Prospectus, a report filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act that cures
such failure or the effectiveness of a Subsequent Form S-3; or

		(iv)	(A) prior to or on the 30th or 45th day, as may be permitted under Section 2(c), of any Suspension Period,
such suspension has not been terminated or (B) Suspension Periods exceed an aggregate of 30 or 45 days, as may be permitted
under Section 2(c), in any 90-day period or an aggregate of 60 days in any 360-day period,

(each such event referred to in foregoing clauses (i)
through (iv), a “Registration Default”), then in such event as partial relief for the damages to any Holder
by reason of any such delay in or reduction of its ability to sell the Registrable Securities and not as a penalty (which remedy
shall constitute liquidated damages, but not be exclusive of any other remedies available at law or equity), the Company hereby
agrees to pay to each Holder, subject to Section 2(e), an amount in cash equal to 1.0% of the product obtained by multiplying
(x) the number of Registrable Securities held by such Holder as of the date of the Registration Default, by (y) the
Closing Price as of the date of the Registration Default (such product, the “Registrable’ Securities Value”),
for each 30-day period (prorated for periods totaling less than 30 days) following the Registration Default during which such
Registration Default remains uncured, up to an aggregate maximum of 10.0% of the Registrable Securities’ Value of such Holder’s
Registrable Securities as of the date of the Registration Default. The payments to which a Holder shall be entitled pursuant to
this Section 2(d) are referred to herein as “Additional Payment Amounts”. The Company shall pay
Additional Payment Amounts, if any, to Holders on the earlier of (I) the last day of the calendar month during which such
Additional Payment Amounts are incurred and (II) the third Business Day following the date on which the Registration Default
giving rise to the Additional Payment Amounts is cured. In the event that the Company fails to pay Additional Payment Amounts in
a timely manner, such Additional Payment Amounts shall accrue interest, payable in cash in arrears, at the rate of 0.25% per month
(prorated for partial months) until paid in full.

(e)               
Selling Holder Agreements. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached
to this Agreement as Annex B (a “Selling Holder Questionnaire”). The Company shall not be required
to include the Registrable Securities of a Holder in a Registration Statement and shall not be required to pay any liquidated or
other damages under Section 2(d) to any Holder who fails to furnish to the Company a fully completed Selling Holder
Questionnaire at least ten Business Days prior to the applicable Filing Deadline.

Each Holder agrees by its acquisition
of such Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described
in Section 2(c) or Section 3(c), such Holder will forthwith discontinue disposition of such Registrable
Securities under the Registration Statement until such Holder’s receipt of the copies of the supplemented Prospectus and/or
amended Registration Statement or until it is advised in writing (the “Advice”) by the Company that the use
of the applicable Prospectus may be resumed. The Company may provide appropriate stop orders to enforce the provisions of this
paragraph.

When Registrable Securities have been
transferred pursuant to a Registration Statement, the transferring Holder shall provide notice to the Company of such transfer
and the number of shares of Registrable Securities so transferred, and certifying that (i) the prospectus delivery requirements
of the 1933 Act have been satisfied or are exempt under Rule 172 thereunder, (ii) the Holder is named as a “Selling Security
Holder” in the Shelf Registration Statement, (iii) the aggregate number of shares of Company Common Stock transferred are
not in excess of those listed in the Shelf Registration Statement as being offered by such Holder, and (iv) the transfer was described
in the section captioned “Plan of Distribution” in the Shelf Registration Statement.

Each Holder agrees to, as expeditiously
as possible, (i) notify the Company of the occurrence of any event that makes any statement made in a Registration Statement or
Prospectus regarding such Holder untrue in any material respect or that requires the making of any changes in a Registration Statement
or Prospectus so that, in such regard, (A) in the case of a Registration Statement, it will not contain any untrue statement of
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not
misleading and (B) in the case of a Prospectus, it will not contain any untrue statement of material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which
they were made, not misleading, (ii) provide the Company with such information as may be required to enable the Company to prepare
a supplement or post-effective amendment to such Registration Statement or a supplement to such Prospectus, and (iii) execute
and deliver such other agreements, instruments or documents, or take such other actions, or refrain from taking such other actions,
as reasonably requested by the Company to implement the terms, conditions, agreements and transactions contemplated by this Agreement.
Each Holder acknowledges and agrees that the performance by the Company of its obligations in respect of such Holder set forth
in Section 2(a) and contained elsewhere in this Agreement are conditioned upon and subject to such Holder’s timely compliance
with its obligations under Section 2(e) and contained elsewhere in this Agreement.

With respect to Registrable Securities
not already covered by a Registration Statement, the Company shall not be obligated to file (i) more than one pre-effective
amendment or supplement to a Registration Statement for all Holders during any fiscal quarter and (ii) more than one post-effective
amendment to a Registration Statement for all Holders during any semi-annual period, and provided further, in all such cases involving
supplements or amendments (whether pre-effective or post-effective), the Company shall only be obligated to make a filing when
the aggregate amount of the Registrable Securities to be included in such amendment or supplement is more than $5.0 million (based
on the average closing price of the Common Stock for the previous 20 trading days).

3.             
Registration Procedures.

(a)               
Right to Prior Drafts. Not less than ten Business Days prior to the filing of a Registration Statement or any amendment
thereto, the Company shall furnish to each Holder copies of the “Selling Stockholders” and “Plan of Distribution”
sections of such documents in the form in which the Company proposes to file them, which sections will be subject to the review
of each such Holder. Each Holder shall provide comments, if any, within five Business Days after the date such materials are provided.
The Company shall not file a Registration Statement or any amendments thereto in which the “Selling Stockholders” or
the “Plan of Distribution” sections thereof differ in any material respect from the disclosure received from a Holder
in its Selling Holder Questionnaire (as amended or supplemented).

(b)              
Subsequent Amendments or Supplements, etc. The Company shall (i) prepare and file with the Commission such amendments,
including post-effective amendments, pursuant to Rule 462 or otherwise, to a Registration Statement and the Prospectus used
in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable
Securities for its applicable Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required
Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably
possible to any comments received from the Commission with respect to any Registration Statement or any amendment thereto; (iv) comply
in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the Registration Statements
and the disposition of all Registrable Securities covered by each Registration Statement; and (v) upon the occurrence of any
event contemplated by Section 3(c)(iv), as promptly as reasonably possible, prepare a supplement or amendment, including
a post-effective amendment, to the affected Registration Statement or a supplement to the related Prospectus or any document incorporated
or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, no Registration
Statement nor any Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

(c)               
Notices to Holders. The Company shall notify the Holders as promptly as reasonably possible (and, in the case of
clause (i)(A) below, not less than two Business Days prior to such filing) and (if requested by any such person) confirm such
notice in writing no later than one Business Day following the day (i)(A) when a Prospectus or any supplement thereto or post-effective
amendment to a Registration Statement is proposed to be filed; and (B) with respect to each Registration Statement or any
post-effective amendment, when the same has become effective; (i) of the issuance by the Commission of any stop order suspending
the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings
for that purpose; (iii) of the receipt by the Company of any notification with respect to the suspension of the qualification
or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening
of any Proceeding for such purpose; and (iv) of the occurrence of any event or passage of time that makes the financial statements
included in a Registration Statement ineligible for inclusion therein or that requires any Registration Statement, Prospectus or
any document incorporated or deemed to be incorporated therein by reference to be revised so that, in the case of such Registration
Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading.

(d)              
Copies. The Company shall furnish to each Holder, without charge, (i) at least one conformed copy of each Registration
Statement and each amendment thereto and all exhibits to the extent requested by such Holder (excluding those previously furnished
or incorporated by reference) promptly after the filing of such documents with the Commission, except if such documents are available
on Edgar; and (ii) as many copies of each Prospectus or Prospectuses (including each form of prospectus) and each amendment
or supplement thereto as such Holder may reasonably request. The Company hereby consents to the use of such Prospectus and each
amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities
covered by such Prospectus and any amendment or supplement thereto.

(e)               
Blue Sky. The Company shall, prior to any public offering of Registrable Securities, use its reasonable commercially
reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification
(or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or
Blue Sky laws of all jurisdictions within the United States that the selling Holders request in writing be covered, to keep each
such registration or qualification (or exemption therefrom) effective during the applicable Effectiveness Period and to do any
and all other acts or things necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities
covered by any Registration Statement; provided that the Company shall not be required to qualify generally to do business
in any jurisdiction where it is not then so qualified, file any general consent to service of process, or to become subject to
any material tax in any such jurisdiction where it is not then so subject.

(f)               
Certificates. The Company shall cooperate with the Holders to facilitate the timely preparation and delivery of certificates
representing Registrable Securities to be delivered to a transferee pursuant to any Registration Statement, which certificates
shall be free of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered
in such names as any such Holders may reasonably request.

(g)              
Subsequent Form S-3. If, at the time of filing of a Registration Statement, the Company is not eligible to use
Form S-3 for transactions involving secondary offerings and the Company is not otherwise eligible to incorporate by reference
prospectively into such Registration Statement, then at such time as the Company becomes eligible to register transactions involving
secondary offerings on Form S-3, the Company may, in its sole discretion, file in accordance with the procedures outlined in this
Section 3, including but not limited to all required notices to the Holders, an additional Registration Statement on
Form S-3 to cover resales pursuant to Rule 415 of the Registrable Securities (a “Subsequent Form S-3”),
and, when such Subsequent Form S-3 has been filed with the Commission, the Company may, concurrently with its filing of a
request for acceleration of effectiveness of such Subsequent Form S-3, withdraw or terminate the original Registration Statement;
provided, however, that nothing in this Section 3(g) shall be interpreted to limit the Company’s obligations
pursuant to Section 2.

(h)              
Underwriters. If underwriters are used or if any Holder is deemed to be, alleged to be or reasonably believes it
may be deemed or alleged to be, an underwriter or is required under applicable securities laws to be described in a Registration
Statement as an underwriter, with the concurrence of counsel for the Company, the Company shall use its reasonable efforts to furnish,
on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through
underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration,
in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters,
and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance
as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed
to the underwriters.

(i)                
144 Information. At such time as the Company becomes subject to Sections 13 or 15(d) of the Exchange Act,
with a view to making available to Holders the benefits of Rule 144 promulgated under the Securities Act, the Company shall
file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and
Exchange Act and provide to any Holder, as long as such Holder owns Registrable Securities, upon reasonable request (i) a
written statement by the Company that it has complied with the current information requirements of Rule 144(c) and (ii) such
other information as may be reasonably requested to avail any Holder of any rule or regulation of the Commission that permits the
selling of any such securities without registration.

4.             
Registration Expenses.

All fees and expenses incident to the
performance of or compliance with this Agreement by the Company, other than underwriting discounts and commissions and any fees
and expenses of legal counsel to any Purchaser(s), shall be borne by the Company whether or not any Registrable Securities are
sold pursuant to a Registration Statement.

5.             
Indemnification.

(a)               
Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and
hold harmless each Holder, the officers, directors, trustees, agents, investment advisors, partners, members, shareholders and
employees of each Holder, each person who controls any Holder (within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act) and the directors, officers, agents or employees of such controlling persons and each underwriter, if any,
and each person who controls any underwriter within the meaning of Section 15 of the Securities Act or Section 20 of
the Exchange Act, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities,
costs (including, without limitation, reasonable costs of preparation and reasonable attorneys’ fees) and expenses (collectively,
“Losses”), as incurred, arising out of or based upon:

(x)any untrue or alleged untrue
statement of a material fact contained in any Registration Statement or any Prospectus;

(y)with respect to any Registration
Statement or Prospectus, any omission or alleged omission of a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading; or

(z)any violation or alleged violation
by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the
Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such Registration Statement,

except with respect to clauses (x)
and (y), to the extent, but only to the extent, that such untrue statements or omissions (1) are made in reliance upon and
in conformity with written information furnished to the Company by or on behalf of any Holder expressly for use in a Registration
Statement, or such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities
and was reviewed and approved in writing by such Holder for use in the Registration Statement, such Prospectus or such form of
Prospectus (it being understood that the Holder has approved Annex A hereto, as may be amended in accordance with the
provisions of this Agreement, for this purpose) or (2) resulted from the use by any Holder of an outdated or defective Prospectus
after the Company has notified such Holder in writing that such Prospectus is outdated or defective and prior to the receipt by
such Holder of an Advice or an amended or supplemented Prospectus, but only if and to the extent that following the receipt of
the Advice or the amended or supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected.
The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of which the Company is
aware in connection with the transactions contemplated by this Agreement.

(b)              
Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company,
its directors, officers, agents and employees, each person who controls the Company (within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act) and the directors, officers, agents or employees of such controlling persons
and any other Holder selling securities under a Registration Statement, any of such other Holder’s partners, directors, officers
or employees, each person who controls such other Holder (within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act) and the partners, directors, officers or employees of such person who controls such other Holder, in each
case to the fullest extent permitted by applicable law from and against all Losses, as incurred, arising solely out of or based
upon any untrue statement of a material fact contained in any Registration Statement or any Prospectus or arising out of or based
upon any omission of a material fact required to be stated therein or necessary to make the statements therein not misleading to
the extent, but only to the extent, that such untrue statements or omissions (1) are made in reliance upon and in conformity
with written information furnished to the Company by or on behalf of any Holder expressly for use in a Registration Statement or
Prospectus, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution
of Registrable Securities and was reviewed and approved in writing by such Holder for use in the Registration Statement or Prospectus
(it being understood that the Holder has approved Annex A hereto, as may be amended in accordance with the provisions of
this Agreement, for this purpose), or (2) resulted from the use by such Holder of an outdated or defective Prospectus after
the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder
of an Advice or an amended or supplemented Prospectus, but only if and to the extent that following the receipt of the Advice or
the amended or supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected. In no event
shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by
such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

(c)               
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any person entitled
to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the person from
whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the
defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees
and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice
shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the
extent that it shall be finally determined by a court of competent jurisdiction, which determination is not subject to appeal or
further review, that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party.

An Indemnified Party shall have the right
to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to
pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and
to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the named parties to any such
Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified
Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such
Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing
that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right
to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall
not be liable for any settlement of any such Proceeding effected without its written consent. No Indemnifying Party shall, without
the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified
Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such Proceeding.

All reasonable fees and expenses of the
Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing
to defend such Proceeding in a manner not inconsistent with this Section 5(c)) shall be paid to the Indemnified Party,
as incurred, within twenty Business Days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately
determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require
such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that
such Indemnified Party is not entitled to indemnification hereunder).

(d)              
Contribution. If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified
Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party,
shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate
to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions
that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party
and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue
or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or
relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a
party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section 5(c), any
reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the
extent such party would have been indemnified for such fees or expenses if the indemnification provided for in Section 5(a)
or 5(b) was available to such party in accordance with its terms. The parties hereto agree that it would not be just and
equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method
of allocation that does not take into account the equitable considerations referred to in this Section 5(d). Notwithstanding
the provisions of this Section 5(d), no Holder shall be required to contribute, in the aggregate, any amount in excess
of the amount by which the proceeds actually received by such Holder from the sale of the Registrable Securities subject to the
Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission.

(e)               
Other. The indemnity and contribution agreements contained in this Section 5 are in addition to any liability
that the Indemnifying Parties may have to the Indemnified Parties.

6.             
Miscellaneous.

(a)               
Notices. Any notice or other communication required or permitted to be provided hereunder shall be in writing and
shall be delivered in person or by first class mail (registered or certified, return receipt requested), facsimile, or overnight
air courier guaranteeing next day delivery, to such address as the recipient shall most recently have designated in writing or,
if no such designation has been made, to the following address:

If to the Company:

5835 Peachtree Corners East, Suite D

Atlanta, Georgia 30092

Attn: Chief Executive Officer

Facsimile: 770-242-8639

With a copy to:

Jones Day

1420 Peachtree Street, N.E.

Suite 800

Atlanta, Georgia 30309

Attn: John E. Zamer

Facsimile: 404-581-8330

If to a Purchaser:

To the address set forth under such Purchaser’s
name on the signature pages hereto.

If to any other person who is then a
registered Holder:

To the address of such Holder as it appears in the record
books of the Company.

All notices and communications (other
than those sent to Holders) shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; five
Business Days after being deposited in the mail, postage prepaid, if mailed; when answered back, if telexed; when receipt acknowledged,
if telecopied; and the next Business Day after timely delivery to the courier, if sent by overnight air courier guaranteeing next
day delivery.

Failure to provide a notice or communication
to one party hereto or any defect in it shall not affect its sufficiency with respect to other parties hereto.

(b)              
Independent Nature of Purchaser’s Obligations and Rights. The obligations of each Purchaser under this Agreement
are several and not joint with the obligations of each other Purchaser, and no Purchaser shall be responsible in any way for the
performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein or in any Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchaser as a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting
in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement or any other Transaction
Document. Each Purchaser acknowledges that no other Purchaser will be acting as agent of such Purchaser in enforcing its rights
under this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation
the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party
in any Proceeding for such purpose. The Company acknowledges that each of the Purchasers has been provided with the same Registration
Rights Agreement for the purpose of closing a transaction with multiple Purchasers and not because it was required or requested
to do so by any Purchaser.

(c)               
No Inconsistent Agreements. The Company will not, on or after the date of this Agreement, enter into any agreement
with respect to its securities that is inconsistent with the rights granted to the Holders in this Agreement or otherwise conflicts
with the provisions hereof. In addition, the Company shall not grant to any of its security holders (other than the Holders) the
right to include any of its securities in a Registration Statement provided for in this Agreement other than the Registrable Securities.
The Company has not previously entered into any agreement (which has not expired or been terminated) granting any registration
rights with respect to its securities to any person which rights conflict with the provisions hereof. None of the Company’s
securityholders other than Holders shall have the right to include any of the Company’s securities in any Registration Statement.

(d)              
Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the
Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement.

(e)               
Remedies. In the event of a breach by the Company or by a Holder of any of their obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this
Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company
and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach
by it of any of the provisions of this Agreement and hereby further agree that, in the event of any action for specific performance
in respect of such breach, it shall waive the defense that a remedy at law would be adequate. In addition, the remedies provided
herein are cumulative and not exclusive of any remedies provided by law.

(f)               
Governing Law; Jurisdiction; Jury Trial; etc. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH,
THE LAWS OF THE STATE OF NEW YORK. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING
OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. If either party shall commence a proceeding to enforce any provisions
of this Agreement, then the prevailing party in such proceeding shall be reimbursed by the other party for its attorney’s
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such proceeding.

(g)              
Amendments and Waivers. No provision of this Agreement may be amended other than by an instrument in writing signed
by the Company and Holders representing a majority of then outstanding Registrable Securities, and any amendment to this Agreement
made in conformity with the provisions of this Section 6(h) shall be binding on the Purchasers and all Holders of the
Registrable Securities, as applicable. No provision hereof may be waived other than by an instrument in writing signed by the party
from whom such waiver is requested. 

(h)              
Entire Agreement. This Agreement supersedes all other prior oral or written agreements among the parties hereto and
persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced
herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically
set forth herein or therein, none of the parties hereto makes any representation, warranty, covenant or undertaking with respect
to such matters.

(i)                
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns; provided that no party shall assign any of its rights or obligations hereunder without the prior
written consent of the other party.

(j)                
Counterparts; Facsimile Copies. This Agreement may be executed in any number of counterparts, each of which when
so executed shall be deemed to be an original and all of which taken together shall constitute one and the same Agreement. In the
event that any signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the
party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature
were the original thereof.

(k)              
Severability. If any provision of this Agreement shall be invalid, unenforceable, illegal or void in any jurisdiction,
such invalidity, unenforceability, illegality or voidness shall not affect the validly or enforceability of the remainder of this
Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.
In that case, the parties hereto shall use their reasonable efforts to find and employ an alternative means to achieve the same
or substantially the same result as that contemplated by such provision. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining provisions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.

(l)                
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.

[Signature Pages Follow]

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

GUIDED THERAPEUTICS, INC.

 

 

By: /s/ Mark L. Faupel________________________

Name: Mark L. Faupel

Title: President and Chief Executive Officer

 

 

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

CRANSHIRE CAPITAL MASTER FUND, Ltd.

 

AUTHORIZED SIGNATORY

By: /s/ Keith A. Goodman ___________________

Name: Keith A. Goodman

Title: Authorized Signatory

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

EQUITEC SPECIALISTS, LLC

 

AUTHORIZED SIGNATORY

By: /s/ Keith A. Goodman ___________________

Name: Keith A. Goodman

Title: Authorized Signatory

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

RONALD HART

 

AUTHORIZED SIGNATORY

By: /s/ Ronald Hart _________________________

Name: Ronald Hart

Title:

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

 

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

CAPITAL VENTURES INTERNATIONAL BY HEIGHTS CAPITAL MANAGEMENT ITS AUTHORIZED AGENT

 

AUTHORIZED SIGNATORY

By: /s/ Martin Kobinger ______________________

Name: Martin Kobinger

Title: Investment Manager

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

JOHN E. IMHOFF

 

AUTHORIZED SIGNATORY

By: /s/ John E. Imhoff _______________________

Name: John E. Imhoff

Title:

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

LYNNE H. IMHOFF

 

AUTHORIZED SIGNATORY

By: /s/ Lynne H. Imhoff _____________________

Name: Lynne H. Imhoff

Title:

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

ALPHA CAPITAL ANSTALT

 

AUTHORIZED SIGNATORY

By: /s/ Konrad Ackermann ___________________

Name: Konrad Ackermann

Title: Director

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

DOLORES MALOOF

 

AUTHORIZED SIGNATORY

By: /s/ Dolores Maloof ______________________

Name: Dolores Maloof

Title:

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

DAVID B. MUSKET 

 

AUTHORIZED SIGNATORY

By: /s/ David B. Musket______________________

Name: David B. Musket

Title:

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

 

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

PROMED PARTNERS, L.P. 

 

AUTHORIZED SIGNATORY

By: /s/ David B. Musket______________________

Name: David B. Musket

Title: General Partner

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________

    	 

    	 

    

IN WITNESS WHEREOF, the parties have
executed this Registration Rights Agreement as of the date first written above.

NAME OF INVESTING ENTITY:

THE WHITTEMORE COLLECTION, LTD.

 

AUTHORIZED SIGNATORY

By: /s/ Stephen J. Suddney____________________

Name: Stephen J. Suddney

Title: Vice President

 

ADDRESS FOR NOTICE

 

c/o: ______________________________________

 

Street: ____________________________________

 

City/State/Zip: _____________________________

 

Attention: _________________________________

 

Tel: ______________________________________

 

Fax: ______________________________________

 

Email: ____________________________________Exhibit 10.1

 

 

Securities
purchase agreement

This Securities Purchase
Agreement (this “Agreement”), is dated as of May 21, 2013, among GUIDED THERAPEUTICS, INC., a Delaware corporation
(the “Company”), and each entity that is listed on the signature pages hereto. Each such entity, together
with its successors and permitted assigns, is referred to herein as a “Purchaser,” and all such entities, together
with their successors and permitted assigns, are collectively referred to herein as the “Purchasers.”

The Company proposes
to issue and sell to the Purchasers an aggregate of up to 3,000 shares of the Company’s Series B Convertible Preferred Stock,
par value $.001 per share (the “Preferred Stock”), at a purchase price of $1,000.00 per share, on the terms
and subject to the conditions set forth in this Agreement.

The Preferred Stock
will have the terms set forth in the certificate of designations designating the Preferred Stock in substantially the form attached
hereto as Exhibit A (the “Preferred Stock Designation”). The Company will file the Preferred Stock Designation
with the Delaware Secretary of State prior to and as a condition to the closing (the “Closing”) of the Transactions
(defined below). The Preferred Stock will be mandatorily convertible into shares of the Company’s common stock, par value
$.001 per share (the “Common Stock”), subject to and in accordance with the terms and conditions of the Preferred
Stock Designation.

The Purchasers will
receive, on a pro rata basis, warrants, in substantially the form set forth in Exhibit B (the “Warrants”)
to acquire up to that number of shares of Common Stock equal to 100% of the number of shares of Common Stock issuable upon conversion
of the Preferred Shares (defined below), rounded to the nearest whole share of Common Stock for each Purchaser. The Warrants issuable
to each Purchaser will be split evenly into two tranches, with one tranche subject to mandatory exercise upon the occurrence of
certain events described therein.

The shares of Preferred
Stock to be sold in the Private Placement are collectively referred to as the “Preferred Shares.” The shares
of Common Stock into which the Preferred Shares are to be convertible are referred to as the “Conversion Shares.”
The shares of Common Stock issuable upon exercise of or otherwise pursuant to the Warrants are referred to as the “Warrant
Shares.” Collectively, the Preferred Shares, the Conversion Shares, and the Warrant Shares are referred to as the “Securities.”
The conversion of the Preferred Stock into Common Stock is referred to herein as the “Conversion”.

The Securities will
be offered and sold to the Purchasers in the private placement without being registered under the Securities Act of 1933, as amended,
and the rules and regulations of the Securities and Exchange Commission (the “Commission”) thereunder (collectively,
the “Securities Act”), in reliance upon Section 4(a)(2) (“Section 4(a)(2)”) thereof and/or
Regulation D (“Regulation D”) thereunder or Regulation S (“Regulation S”) thereunder. The
Company has engaged SunTrust Robinson Humphrey to act as exclusive placement agent (the “Placement Agent”) for
the offering of the Securities on a “best efforts” basis.

Holders of the Securities
will be entitled to the benefits of a Resale Registration Rights Agreement (the “Resale Registration Rights Agreement”)
to be entered into between the Company and the Purchasers pursuant to which the Company will agree, among other things, to file
with the Commission a shelf registration statement pursuant to Rule 415 under the Securities Act (the “Resale Registration
Statement”) covering the resale of the Conversion Shares and the Warrant Shares, and to use its commercially
reasonable efforts to cause the Resale Registration Statement to be declared effective within the time periods specified in the
Resale Registration Rights Agreement.

The number of Preferred
Shares to be purchased by each Purchaser hereunder is set forth on such Purchaser’s signature page. Each of the Purchasers
is acting separately.

This Agreement, the
Preferred Stock Designation, the form of Warrant, and the Resale Registration Rights Agreement are referred to herein collectively
as the “Transaction Documents,” and the transactions contemplated hereby and thereby are referred to herein
collectively as the “Transactions.”

The Company hereby
confirms its agreement with each Purchaser as follows:

Section 1. Purchase
and Sale of Securities.

(a)               
Closing; Closing Date. Subject to the satisfaction or, where possible, waiver of the conditions set forth in Sections
5 and 6, at the closing (the “Closing”), the Company shall issue and sell to the Purchasers, and
each Purchaser severally agrees to purchase from the Company on the Closing Date (as defined below), the amount of Preferred Shares
and Warrants set forth on such Purchaser’s signature page to this Agreement. The date and time of the Closing (the “Closing
Date”) shall be 10:00 a.m., New York City time, on a date as soon as practicable after the date hereof and as mutually
agreed to by the Company and the Purchasers, but in no event later than the tenth business day following the date of this Agreement;
provided, however, that if the Closing has not taken place on the Closing Date because of a failure to satisfy one
or more of the conditions specified in Sections 5 or 6, “Closing Date” shall mean 10:00 a.m.,
New York City Time, on the first business day following satisfaction or waiver of all such conditions) after notification of satisfaction
or waiver of the conditions to the Closing set forth in Sections 5 and 6. The Closing shall take place
at the offices of Jones Day, Atlanta, Georgia.

(b)              
Form of Payment. Except as may otherwise be agreed to among the Company and one or more of the Purchasers, on or
prior to 12:00 p.m., New York City time, on the Closing Date, (i) each Purchaser shall wire its Investment Amount (as set forth
on, and as defined in, each Purchaser’s signature page to this Agreement), in U.S. dollars and in immediately available funds,
to the Company pursuant to the wire instructions set forth in Schedule 1; (ii) the Company shall irrevocably instruct the
Transfer Agent to deliver to each Purchaser (pursuant to instructions set forth in the Investor Questionnaire attached as Exhibit
C) one or more stock certificates, free and clear of all restrictive legends (except as expressly provided in this Agreement),
evidencing the number of Preferred Shares such Purchaser is purchasing as is set forth on such Purchaser’s signature page
to this Agreement next to the heading “Number of Securities to be Acquired,” within one business day after the Closing;
and (iii) the Company shall deliver to each Purchaser (pursuant to instructions set forth in the Investor Questionnaire attached
as Exhibit C) two or more Warrants (divided equally by Warrant Shares among two tranches, one tranche subject to mandatory
exercise upon the occurrence of certain events described therein), free and clear of all restrictive legends (except as expressly
provided in this Agreement), exercisable for that number of Warrant Shares equal to 100% of the number of Conversion Shares issuable
to such Purchaser upon Conversion of such Purchaser’s Preferred Shares on the Closing Date, rounded to the nearest whole
share of Common Stock.

Section 2. Representations
and Warranties of Each Purchaser.

Each Purchaser, for
itself and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing Date to the Company and
the Placement Agent as follows:

(a)               
Private Placement; Reliance on Exemptions. Such Purchaser understands that the Securities are being offered and sold
to it in reliance on Section 4(a)(2), Regulation D or Regulation S under the Securities Act from the registration requirements
of U.S. federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser’s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth herein
in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities.

(b)              
Purchaser Status. Each of the Purchasers acknowledges that (i) (A) it is an institutional “accredited investor”
as defined in Rule 501(a)(1), (2), (3) or (7) of Regulation D under the Securities Act and/or meets the definition of “qualified
institutional buyers” as defined in Rule 144A(a)(1) under the Securities Act and (B) is not an entity formed for the sole
purpose of acquiring the Securities; or (ii) it is not purchasing the Securities as a result of any “directed selling efforts,”
within the meaning of Rule 902(k) of Regulation S and that such Purchaser is not a “U.S. Person,” within the meaning
of Rule 902(k) of Regulation S and it is purchasing the Securities pursuant to an offshore transaction, as such terms are used
in Regulation S.

(c)               
No Public Sale or Distribution. Such Purchaser is acquiring the Securities for its own account and not with a view
toward, or for resale in connection with, the public sale or distribution thereof in a manner that would violate the Securities
Act; provided, however, that by making the representations herein, such Purchaser does not agree to hold any of the Securities
for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant
to a registration statement or an exemption under the Securities Act. Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business. Such Purchaser does not presently have any agreement or understanding, directly or indirectly,
with any Person to distribute any of the Securities. As used in this Agreement, “Person” means an individual,
a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government
or any department or agency thereof.

(d)              
Independent Evaluation. Such Purchaser confirms and agrees that (i) it has independently evaluated the merits of
its decision to purchase the Securities; (ii) such Purchaser and its advisors, if any, have been afforded the opportunity to ask
questions of and receive answers from the Company; with the understanding that neither such inquiries nor any other due diligence
investigations conducted by such Purchaser or its advisors, if any, or its representatives shall modify, amend or affect such Purchaser’s
right to rely on the Company’s representations and warranties contained herein; (iii) its investment in the Securities involves
a high degree of risk and it is able to bear the economic risk of such investment; (iv) it has sufficient knowledge and experience
in financial and business matters as to be capable of evaluating the merits and risks of its investment in the Securities and has
sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect
to its acquisition of the Securities; (v) it has not relied on the advice of, or any representations by, the Placement Agent or
any affiliate thereof or any representative of the Placement Agent or its affiliates in making such decision; and (vi) neither
the Placement Agent nor any of its representatives has any responsibility with respect to the completeness or accuracy of any information
or materials furnished to such Purchaser in connection with the Transactions.

(e)               
Legend(s). Such Purchaser understands that upon the original issuance thereof, and until such time as the same is
no longer required under applicable requirements of the Securities Act or applicable state securities laws, the certificates or
other instruments representing the Securities, and all certificates or other instruments issued in exchange therefor or in substitution
thereof, shall bear customary legend(s) referencing such restrictions on transferability, and that the Company will make a notation
on its records and give instructions to any transfer agent of the Common Stock in order to implement the restrictions on transfer
set forth and described herein.

(f)               
Organization; Authority. Such Purchaser is an entity duly organized, validly existing and in good standing under
the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

(g)              
Validity; Enforcement. This Agreement and the Resale Registration Rights Agreement have been authorized by all necessary
corporate action of, and duly and validly executed and delivered on behalf of, such Purchaser and constitute the legal, valid and
binding obligations of such Purchaser enforceable against such Purchaser in accordance with their respective terms, except as such
enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies.

(h)              
No Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and the Resale Registration
Rights Agreement and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result
in a violation of the organizational documents of such Purchaser or (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any material agreement, indenture or instrument to which such Purchaser is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree applicable to such Purchaser, except in the case of clauses (ii)
and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably
be expected to have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder.

(i)                
No Governmental Review. Such Purchaser understands that no U.S. agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

(j)                
Transfer or Resale. Such Purchaser understands that: (i) the Securities have not been and will not be registered
under the Securities Act or any U.S. state or non-U.S. securities laws; (ii) such Purchaser agrees that if it decides to offer,
sell or otherwise transfer any of the Securities, such Securities may be offered, sold or otherwise transferred only: (A) pursuant
to an effective registration statement under the Securities Act; (B) to the Company; (C) outside the United States in accordance
with Regulation S under the Securities Act and in compliance with local laws; or (D) within the United States (1) in accordance
with the exemption from registration under the Securities Act provided by Rule 144A thereunder, if available, and in compliance
with any applicable state securities laws, or (2) in a transaction that does not require registration under the Securities Act
or applicable state securities laws.

(k)              
Filings. If required by applicable securities legislation, regulatory policy or order, or if required or requested
by any securities commission, stock exchange or other regulatory authority, at the request of and at the sole expense of the Company,
such Purchaser will use commercially reasonable efforts to execute, deliver and file and otherwise assist the Company in filing
reports, questionnaires, undertakings and other documents with respect to the issue of the Securities.

(l)                
Residency. For purposes of U.S. securities laws, such Purchaser is a resident of that jurisdiction specified on its
signature page to this Agreement.

(m)            
U.S. Federal Taxation. Such Purchaser acknowledges that it has sought advice concerning the tax aspects of and tax
considerations involved in acquiring and holding the Securities from an independent tax adviser that it has considered necessary
to make an informed investment decision with respect to the U.S. federal income tax consequences, as well as with respect to the
laws of any state, local or foreign jurisdiction that are applicable to such Purchaser, of owning and disposing of the Securities.

Section 3. Representations
and Warranties of the Company.

Except as otherwise
disclosed in the Exchange Act Documents (as defined below), the Company hereby represents and warrants as of the date hereof and
the Closing Date (except for the representations and warranties that speak as of a specific date, which are made as of such date),
to each of the Purchasers and the Placement Agent as follows:

(a)               
Exchange Act Compliance. The Company has filed with the Commission all documents (the “Exchange Act Documents”)
required since January 1, 2012 under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
thereunder (collectively, the “Exchange Act”), and the Exchange Act Documents, at the time they were filed with
the Commission, complied in all material respects with the requirements of the Exchange Act. There are no contracts or other documents
required to be described in such Exchange Act Documents or to be filed as exhibits to such Exchange Act Documents that have not
been described or filed as required.

(b)              
The Transaction Documents. The Company has all necessary power and authority to execute and deliver the Transaction
Documents and to perform its obligations thereunder; each of the Transaction Documents has been duly authorized by the Company
and, when executed and delivered by the Company, will constitute a valid and binding agreement of the Company, enforceable against
the Company in accordance with its terms.

(c)               
The Securities. The Company has all necessary power and authority to issue and deliver the Preferred Shares; the
Preferred Shares have been duly authorized, and, when duly issued and delivered to Purchasers, will be duly and validly issued,
fully paid and nonassessable and will be issued in compliance with federal and state securities laws. The Company has all necessary
power and authority to execute, issue and deliver the Warrants; the Warrants have been duly authorized for issuance and sale by
the Company, will be in the form contemplated by the Transaction Documents and, when executed, countersigned and issued in accordance
with the terms of thereof and delivered to and paid for by the Purchasers pursuant to this Agreement, will constitute valid and
binding obligations of the Company, entitled to the benefits of the Transaction Documents, enforceable against the Company in accordance
with their terms. The Company has all necessary power and authority to issue and deliver the Conversion Shares and the Warrant
Shares; the Conversion Shares and the Warrant Shares have been duly reserved for issuance and have been duly authorized, and, when
duly issued and delivered to holders of the Preferred Shares or the Warrants upon Conversion or upon exercising of the Warrants
from time to time, respectively, the Conversion Shares and the Warrant Shares will be duly and validly issued, fully paid and nonassessable
and will be issued in compliance with federal and state securities laws. None of the Securities will be issued in violation of
any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company.

(d)              
No Applicable Registration or Other Similar Rights. There are no Persons with registration or other similar rights
to have any equity or debt securities of the Company or any affiliate (as defined in Rule 501(b) of Regulation D) registered for
sale under a registration statement, except for rights (i) contained in the Resale Registration Rights Agreement or (ii) as have
been duly waived.

(e)               
No Material Adverse Change. Since December 31, 2012: (i) there has been no material adverse change, or any development
that would reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings,
business, operations or prospects, whether or not arising from transactions in the ordinary course of business, of the Company
and its subsidiary, considered as one entity (any such change, a “Material Adverse Change”); and (ii) the Company
and its subsidiary, considered as one entity, have not incurred any material liability or obligation (including any off-balance
sheet obligation), indirect, direct or contingent, not in the ordinary course of business nor entered into any material transaction
or agreement not in the ordinary course of business.

(f)               
Independent Accountants. UHY LLP, who have expressed their opinion with respect to the financial statements (which
term as used in this Agreement includes the related notes thereto) contained in the Exchange Act Documents, are (i) independent
public or certified public accountants as required by the Exchange Act, (ii) in compliance with the applicable requirements relating
to the qualification of accountants under Rule 2-01 of Regulation S-X and (iii) a registered public accounting firm as defined
by the Public Company Accounting Oversight Board.

(g)              
Preparation of the Financial Statements. As of the date hereof, the financial statements contained in the Exchange
Act Documents, present fairly in all material respects the consolidated financial position of the Company and its subsidiary as
of and at the dates indicated and the results of their operations and cash flows for the periods specified. Such financial statements
have been prepared in conformity in all material respects with generally accepted accounting principles as applied in the United
States applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto.
As of the date hereof, the financial data set forth in the Exchange Act Documents fairly present the information set forth therein
on a basis consistent with that of the audited financial statements contained in the Exchange Act Documents.

(h)              
Incorporation and Good Standing of the Company and its Subsidiary. Each of the Company and its subsidiary has been
duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation
and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in
the Exchange Act Documents as of their date, and, in the case of the Company, to enter into and perform its obligations under the
Transaction Documents. Each of the Company and its subsidiary is duly qualified as a foreign corporation to transact business and
is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure to be so qualified would not, individually or in the aggregate,
have a material adverse effect on the financial position, stockholders’ equity, results of operations or business of the
Company (a “Material Adverse Effect”).

(i)                
Capital Stock Matters. Schedule 3(i) sets forth as of the date hereof: (1) the authorized, issued and
outstanding capital stock of the Company, (2) the shares of Common Stock issuable upon exercise of outstanding options, (3) the
shares of Common Stock issuable upon exercise of outstanding warrants or warrants the Company is contractually obligated to issue,
(4) the shares of Common Stock reserved pursuant to its stock option plan, and (5) the shares of Common Stock reserved pursuant
to other contractual obligations. All of the issued and outstanding shares of Common Stock have been duly authorized and validly
issued, are fully paid and nonassessable and have been issued in compliance with federal and state securities laws. None of the
outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal or other similar
rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive
rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable
for, any capital stock of the Company or its subsidiary other than those described in Schedule 3(i). As of the date hereof
and as of the Closing Date, the description of the Company’s stock option, stock bonus and other stock plans or arrangements,
and the options or other rights granted thereunder, as set forth in the Exchange Act Documents constitutes and will constitute
an accurate summary of the material terms and related issuances with respect to such plans, arrangements, options and rights.

(j)                
Exchange Act Registration; No Shell-Company Status. The shares of Common Stock are registered pursuant to Section
12(g) of the Exchange Act, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company is not, and has never been, a “shell company” for purposes of Rule 144(i)
of the Securities Act.

(k)              
Purchasers; Compliance With Rule 502(d). The Company will exercise reasonable care to assure that the Purchasers
are not “underwriters” within the meaning of Section 2(a)(11) of the Securities Act and, without limiting the foregoing,
that such purchases will comply with Rule 502(d) under the Securities Act.

(l)                
Compliance with Laws. The Company has not been advised, and has no reason to believe, that it and its subsidiary
are not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting
business, except where failure to be so in compliance would not result in a Material Adverse Change.

(m)            
No Violation or Default. The Company and its subsidiary are not in, and the execution, delivery and performance of
the Transaction Documents by the Company and the consummation by the Company of the Transactions will not result in a, (i) violation
of any term of or in default under its certificate of incorporation, bylaws or other organizational document, (ii) violation of
any judgment, decree or order or any law, statute, ordinance, rule or regulation (including federal U.S. and state and non-U.S.
securities laws) applicable to the Company and its subsidiary, and the Company and its subsidiary will not conduct their business
in violation of any of the foregoing, and (iii) in default, and no event has occurred that, with notice or lapse of time or both,
would constitute such a default, in the due performance or observance of any material term, covenant or condition contained in,
or give to others any rights of termination, amendment, acceleration or cancellation of, any indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument to which the Company or its subsidiary is a party or by which the Company or its
subsidiary are bound or to which any of the property or assets of the Company or its subsidiary is subject, except, in the case
of clauses (ii) and (iii), for such violations as would not be reasonably expected to have a Material Adverse Effect.

(n)              
Consents. Other than (1) the filing of a Form D with respect to the Securities as required under Regulation D, (2)
such filings required under applicable securities or Blue Sky laws of the states of the United States, and (3) such filings contemplated
by the Resale Registration Rights Agreement (all of the foregoing, the “Required Approvals”), the Company and
its subsidiary are not required to obtain any consent, approval, authorization or order of, or make any filing or registration
with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for the Company to
execute, deliver or perform any of its obligations under or contemplated by the Transaction Documents, in each case, in accordance
with the terms hereof or thereof or to consummate the Transactions.

(o)              
No Directed Selling Efforts. None of the Company, its affiliates nor any Person acting on its or their behalf (other
than the Placement Agent in connection with this Agreement) has engaged or will engage in any directed selling efforts (as that
term is defined in Regulation S) with respect to the Securities and each of the Company, its affiliates and any Person acting on
its or their behalf (other than the Placement Agent in connection with this Agreement) has complied and will comply with the offering
restrictions requirement of Regulation S.

(p)              
No Registration. Assuming the accuracy of the representations and warranties of the Purchaser contained in Section
2 and each Purchaser’s compliance with their agreements set forth in the Transaction Documents, it is not necessary in
connection with the offer, issuance, sale and delivery of the Securities in the manner contemplated by this Agreement and the other
Transaction Documents to register the offer or sale of any of the Securities under the Securities Act.

(q)              
No General Solicitation. Neither the Company, nor any of its affiliates, nor any Person acting on its behalf, has
engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the
offer or sale of the Securities.

(r)                
No Integrated Offering. Neither the Company, nor any of its affiliates, or any Person acting on its behalf, has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would require registration of any of the Securities under the Securities Act or cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of the Securities Act. None of the Company, its affiliates, or any
Person acting on its behalf, will take any action or steps referred to in the preceding sentence that would require registration
of the offer, issuance or sale of any of the Securities under the Securities Act or cause the offering of the Securities to be
integrated with other offerings.

(s)               
No Offer and Sale Within Six Months. The Company has not sold or issued any security of the same or similar class
or series as any of the Securities or any security convertible into any of the Securities during the six-month period preceding
the earlier of the date of this Agreement and the Closing Date, including any sales pursuant to Rule 144A or Regulation D (other
than shares issued pursuant to employee or director benefit plans, qualified stock options plans, for other employee or director
compensation purposes, or pursuant to outstanding options, rights or warrants), and has no intention of making, and will not make,
an offer or sale of such securities, for a period of six months after the date of this Agreement, except for the offering of Securities
as contemplated by this Agreement and the Resale Registration Rights Agreement. As used in this paragraph, the terms “offer”
and “sale” have the meanings specified in Section 2(a)(3) of the Securities Act.

(t)                
QIBs; Accredited Investor or Non-U.S. Person. The Company will not offer or sell any of the Securities to any Person
whom it reasonably believes is not (i) a “qualified institutional buyer” as defined in Rule 144A; (ii) an institutional
“accredited investor” (as defined in clauses (1), (2), (3) and (7) of Rule 501(a) of Regulation D); or (iii) a non-U.S.
Person as defined under Regulation S of the Securities Act.

(u)              
All Necessary Permits, etc. The Company and its subsidiary each possess such valid and current certificates, authorizations
or permits issued by the appropriate state, federal or other applicable regulatory agencies or bodies necessary to conduct their
respective businesses, and neither the Company nor its subsidiary has received any notice of proceedings relating to the revocation
or modification of, or non-compliance with, any such certificate, authorization or permit that, singly or in the aggregate, if
the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change.

(v)              
Intellectual Property Rights. The Company and its subsidiary own or possess sufficient trademarks, service marks,
trade names, patents, patent rights, copyrights, domain names, licenses, approvals, trade secrets, inventions, know-how (including
unpatented and/or unpatentable proprietary or confidential information, systems or procedures), licenses and other similar rights
(collectively, “Intellectual Property Rights”) reasonably necessary to conduct their businesses as now conducted.
Neither the Company nor its subsidiary has received any notice of infringement or conflict with asserted Intellectual Property
Rights of others. As of the date hereof and as of the Closing Date, the Company is not and will not be a party to or bound by any
material options, licenses or agreements with respect to the Intellectual Property Rights of any other Person except as described
in the Exchange Act Documents or as will be described in the Exchange Act Documents. None of the technology employed by the Company
has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the
Company’s knowledge, any of its officers, directors or employees or otherwise in violation of the rights of any Persons.

(w)            
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, government
agency, self-regulatory organization or body pending or, to the best knowledge of the Company, (i) threatened against or affecting
the Company, its subsidiary, or any of the officers or directors of the Company or its subsidiary in their capacities as such or
(ii) that questions the validity of the Transaction Documents or the right of the Company to enter into or perform the Transaction
Documents, nor is there any litigation pending or, to the Company's knowledge, threat thereof, against the Company or its subsidiary
by reason of the activities presently conducted or proposed to be conducted by the Company or its subsidiary, nor, to the Company’s
knowledge, is there any basis therefor.

(x)              
Insurance. Each of the Company and its subsidiary are insured by recognized, financially sound and reputable institutions
with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary
for their businesses including, but not limited to, policies covering real and personal property owned or leased by the Company
and its subsidiary against theft, damage, destruction, acts of vandalism and earthquakes. The Company has no reason to believe
that it or its subsidiary will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii)
to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted
and at a cost that would not result in a Material Adverse Change. Neither of the Company nor its subsidiary has been denied any
insurance coverage which it has sought or for which it has applied.

(y)              
Tax Law Compliance. The Company and its consolidated subsidiary have filed all necessary federal and state income
and franchise tax returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them
and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested
in good faith and by appropriate proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial
statements referred to in Section 3(g) in respect of all federal and state and income and franchise taxes for all periods
as to which the tax liability of the Company or its consolidated subsidiary has not been finally determined.

(z)               
Company Not an “Investment Company.” The Company is not, and after receipt of payment for the Securities
will not be, an “investment company” within the meaning of the Investment Company Act of 1940, as amended, and the
rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”) and will conduct
its business in a manner so that it will not become subject to the Investment Company Act.

(aa)           
Brokers. Except for the Placement Agent, there is no broker, finder or other party that is entitled to receive from
the Company any brokerage or finder’s fee or other fee or commission as a result of the Transactions.

Section 4. Covenants.

(a)               
Reasonable Best Efforts. Each party shall use its reasonable best efforts to timely satisfy each of the conditions
to be satisfied by it as provided in Sections 5 and 6 of this Agreement.

(b)              
Form D and Blue Sky. The Company agrees to file a Form D with respect to the Securities as required under Regulation
D and to comply with any applicable state securities and “Blue Sky” laws in connection with the sale of the Securities.
The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary in order
to obtain an exemption for or to qualify the Securities for sale to the Purchasers at the Closing pursuant to this Agreement under
applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification),
and shall provide evidence of any such action so taken to the Purchasers on or prior to the Closing Date. The Company shall make
all filings and reports relating to the offer and sale of the Securities required under applicable securities or “Blue Sky”
laws of the states of the United States following the Closing Date.

(c)               
Securities Laws Disclosure; Publicity. No later than
9:30 a.m., New York City time, on the first business day after the date of this Agreement, the Company shall issue a press release
(the “Press Release”) in a form reasonably acceptable
to the Placement Agent disclosing all material terms of the Transactions. On or before 5:30 p.m., New York City time, on the fourth
business day immediately following the execution of this Agreement, the Company will file a current report on Form 8-K with the
Commission describing the terms of the Transaction Documents (and including as exhibits to such current report on Form 8-K the
Transaction Documents). Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser or an
Affiliate of any Purchaser, or include the name of any Purchaser or an Affiliate of any Purchaser in any press release or filing
with the Commission (other than the Registration Statement) or any regulatory agency, without the prior written consent of such
Purchaser, except (1) as required by federal securities law in connection with (A) any registration statement contemplated
by the Resale Registration Rights Agreement and (B) the filing of final Transaction Documents (including signature pages thereto)
with the Commission and (2) to the extent such disclosure is required by law or request of the Staff of the Commission, in
which case the Company shall provide the Purchasers with prior written notice of such disclosure permitted under this subclause
(2). From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information
received from the Company or any of its officers, directors, employees or agents, that is not disclosed in the Press Release, unless
a Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. Each Purchaser,
severally and not jointly with the other Purchasers, covenants that it will comply with the provisions of any confidentiality or
nondisclosure agreement executed by it and, in addition, until such time as the transactions contemplated by this Agreement are
required to be publicly disclosed by the Company as described in this Section 4(c), such Purchaser will maintain the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). 

(d)              
Fees and Expenses. Each party to this Agreement shall bear its own expenses in connection with the offer and sale
of the Securities to the Purchasers. The Company shall pay the fees of its transfer agent in connection with the offer and sale
of the Securities to the Purchasers.

(e)               
Financial Information. For so long as any Securities remain outstanding, the Company will make available to the Purchasers
and any holder of Securities in connection with any sale thereof and any prospective purchaser of Securities, in each case upon
request, the information specified in, and meeting the requirements of, Regulation D under the Securities Act (or any successor
thereto).

(f)               
Reporting Status. During the period beginning on the Closing Date and ending on the earlier of the second anniversary
of the Closing Date and the date none of the Securities remain outstanding, the Company shall timely file all reports required
to be filed with the Commission pursuant to the Exchange Act, and the Company shall not terminate its status as an issuer required
to file reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would no longer require
or otherwise permit such termination.

(g)              
Reservation of Shares. The Company shall take all action necessary to at all times have authorized, and reserved
for the purpose of issuance, free of pre-emptive rights, after the Closing Date, a number of shares of Common Stock sufficient
for the purpose of enabling the Company to issue the Conversion Shares upon the Conversion and the Warrant Shares upon exercise
of the Warrants.

(h)              
Issuance Limitation. During the period beginning on the date of this Agreement and ending on the 30th day following
the Effective Date (as defined in the Resale Registration Rights Agreement), the Company shall not issue, sell or exchange, or
agree or obligate itself to issue, sell or exchange or reserve, agree to or set aside for issuance, sale or exchange, (1) any shares
of Common Stock, (2) any other equity security of the Company, including, without limitation, shares of preferred stock, (3) any
other security of the Company which by its terms is convertible into or exchangeable or exercisable for any equity security of
the Company, or (4) any option, warrant or other right to subscribe for, purchase or otherwise acquire any such security described
in the foregoing clauses (1) through (3); provided, however, that the foregoing shall not apply to any issuance of
shares of Common Stock or Common Stock equivalents (A) upon the exercise of any options or warrants outstanding, (B) upon the exercise
of any Warrants or upon the Conversion, or (C) to employees, directors, or consultants pursuant to any stock option or equity incentive
plan or other compensation plan, program, agreement or arrangement as long as, in the case of clauses (A) and (C), the terms of
any such options, warrants, plan, programs, agreements, or arrangements are not materially amended.

Section 5. Conditions
to the Company’s Obligation to Sell.

The obligation of the
Company hereunder to issue and sell the Securities to the Purchasers at the Closing is subject to the satisfaction, at or before
the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit
and may be waived by the Company at any time in its sole discretion by providing the Purchaser with prior written notice thereof:

(a)               
Each Purchaser shall have executed each of the Transaction Documents to which it is a party and delivered the same to the
Company, and shall have delivered to the Company a fully completed and executed Investor Questionnaire, satisfactory to the Company,
in the form attached as Exhibit C to this Agreement and Selling Stockholder Questionnaire, satisfactory to the Company,
in the form attached as Annex B to the Registration Rights Agreement.

(b)              
Each Purchaser shall have delivered to the Company such Purchaser’s Investment Amount no later than 12:00 p.m. New
York City time on the Closing Date by wire transfer of immediately available funds pursuant to the wire instructions set forth
on Schedule 1 hereto.

(c)               
The representations and warranties of each Purchaser contained herein shall be true and correct as of the date when made
and as of the Closing Date as though made at that time and such Purchaser shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied
with by such Purchaser, as applicable, at or prior to the Closing Date.

(d)              
No injunction, restraining order, action or order of any nature by a governmental or regulatory authority shall have been
issued, taken or made or no action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted
or issued by any federal, state or foreign governmental or regulatory authority of competent jurisdiction that would, prior to
or as of the Closing Date, prevent or materially interfere with the consummation of the Transactions.

Section 6. Conditions
to the Purchasers’ Obligation to Purchase.

The obligation of each
Purchaser hereunder to purchase the Securities at the Closing is subject to the satisfaction, at or before the Closing Date, of
each of the following conditions, provided that these conditions are for the Purchasers’ several and sole benefit
and may be waived by each Purchaser at any time in such Purchaser’s sole discretion by providing the Company with prior written
notice thereof:

(a)               
The Company shall have executed and delivered, or caused to be delivered, to each Purchaser (i) each of the Transaction
Documents to which it is a party; (ii) pursuant to instructions set forth in the Investor Questionnaire attached as Exhibit
C, facsimile copies of one or more stock certificates, free and clear of all restrictive legends except as provided for in
this Agreement, evidencing the number of Preferred Shares such Purchaser is purchasing as is set forth on such Purchaser’s
signature page to this Agreement next to the heading “Number of Preferred Shares to be Acquired,” with the original
stock certificates delivered by the Company’s transfer agent within one business day after the Closing; and (iii) and
two or more Warrants exercisable, in the aggregate, for that number of Warrant Shares equal to 100% of the number of Conversion
Shares issuable to such Purchaser upon Conversion of such Purchaser’s Preferred Shares on the Closing Date (divided equally
by Warrant Shares among two tranches, one tranche subject to mandatory exercise upon the occurrence of certain events described
therein), rounded to the nearest whole share of Common Stock.

(b)              
The representations and warranties of the Company contained herein shall be true and correct as of the date when made and
as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date,
which shall have been true and correct as of such date) and the Company shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied
with by the Company, as applicable, at or prior to the Closing Date. Each Purchaser or its agent shall have received a certificate,
executed by an authorized officer of the Company, dated as of the Closing Date, to the foregoing effect.

(c)               
No injunction, restraining order, action or order of any nature by a governmental or regulatory authority shall have been
issued, taken or made or no action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted
or issued by any federal, state or foreign governmental or regulatory authority of competent jurisdiction that would, prior to
or as of the Closing Date, prevent or materially interfere with the consummation of the Transactions; and no stop order suspending
the qualification or exemption from qualification of any of the Securities in any jurisdiction shall have been issued and no proceeding
for that purpose shall have been commenced or, to the knowledge of the Company, be pending or contemplated as of the Closing Date.

(d)              
The Company shall not have received any material non-public communications (verbal or written) from the U.S. Food and Drug
Administration pertaining to the regulatory review of the LuViva product for cervical cancer.

(e)               
There shall not have occurred any event or condition which has had, or would reasonably be expected to have, a material
adverse effect on the Company’s business, financial condition, results of operations, assets, liabilities or prospects, in
each case taken as a whole.

(f)               
Each Purchaser or its agent shall have received an opinion of Jones Day, counsel to the Company, dated the Closing Date,
addressed to each such Purchaser, in substantially the form attached hereto as Exhibit D, and the Placement Agent shall
have received a customary reliance letter with regard to such opinion.

(g)              
The Company shall have delivered duly executed irrevocable transfer agent instructions acknowledged in writing by the Company’s
transfer agent instructing the transfer agent to deliver the certificates referred to in Section 6(a).

(h)              
The Company shall have delivered to each Purchaser a Secretary’s certificate certifying to (i) the formation and good
standing of the Company in its jurisdiction of organization; (ii) qualification by such entity as a foreign corporation and good
standing issued by the Secretary of State of the State of Georgia as of a date within 30 days of the Closing Date; and (iii) (a)
the resolutions as adopted by the Company’s Board of Directors authorizing the Transaction Documents and the Transactions,
and (b) the accuracy of attached copies of the certificate of incorporation and bylaws of the Company and such other matters as
reasonably requested by the Purchasers and as are customary for similar transactions.

Section 7. Termination;
Survival. This Agreement may be terminated and the sale and purchase of the Securities abandoned
at any time prior to the Closing by either the Company or any Purchaser (with respect to itself only) upon written notice to the
other, if the Closing has not been consummated on or prior to 5:00 p.m., New York City time, on the 11th business day
after the date of this Agreement; provided, however, that the right to terminate this Agreement under this Section
7(a) shall not be available to any party whose failure to comply with its obligations under this Agreement has been the cause
of or resulted in the failure of the Closing to occur on or before such time. Nothing in this Section 7(a) shall be deemed
to release any party from any liability for any breach by such party of the terms and provisions of the Transaction Documents or
to impair the right of any party to compel specific performance by any other party of its obligations under the Transaction Documents.
In the event of a termination pursuant to this Section 7(a), the Company shall promptly notify all non-terminating Purchasers.
Upon a termination in accordance with this Section 7(a), the Company and the non-terminating Purchaser(s) shall not have
any further obligation or liability (including arising from such termination) to the other, and no Purchaser will have any liability
to any other Purchaser under the Transaction Documents as a result therefrom. 

Section 8. Indemnification.

(a)               
In consideration of each Purchaser’s execution and delivery of the Transaction Documents and acquiring the Securities
thereunder and in addition to all of the other obligations of the Company under the Transaction Documents, the Company shall defend,
protect, indemnify and hold harmless each Purchaser and such Purchasers’ stockholders, partners, members, officers, directors,
employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives (including,
without limitation, those retained in connection with the transactions contemplated by this Agreement) (each, an “Indemnitee”
and collectively, the “Indemnitees”), as incurred, from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether
any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’
fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising
out of, or relating to the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby. To the extent that the foregoing undertaking by each of the Company may
be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the
Indemnified Liabilities which is permissible under applicable law. If a third party claim in respect of Indemnified Liabilities
involves more than one Indemnitee, the Indemnitees shall conduct the defense through the same legal counsel, at indemnitor’s
expense, acceptable to all Indemnitees, provided that an Indemnitee may employ separate counsel, at indemnitor’s expense,
if representation by the same legal counsel would be inappropriate due to differing interests between the Indemnitees.

Section 9. Miscellaneous.

(a)               
Notices. Any notice or other communication required or permitted to be provided hereunder shall be in writing and
shall be delivered in Person or by first class mail (registered or certified, return receipt requested), facsimile, or overnight
air courier guaranteeing next day delivery. The address for such notices and communications shall be as follows:

If to the Company:

5835 Peachtree Corners East, Suite D

Atlanta, Georgia 30092

Attn: Chief Executive Officer

Facsimile: 770-242-8639

With a copy to:

Jones Day

1420 Peachtree Street, N.E.

Suite 800

Atlanta, Georgia 30309

Attn: John E. Zamer

Facsimile: 404-581-8330

If to a Purchaser:

To the address set forth under such Purchaser’s
name on its signature page to this Agreement, or such other address as may be designated in writing hereafter by such Purchaser.

All notices and communications
shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; five business days after being
deposited in the mail, postage prepaid, if mailed; when receipt acknowledged, if telecopied; and the next business day after timely
delivery to the courier, if sent by overnight air courier guaranteeing next day delivery. Failure to provide a notice or communication
to one party hereto or any defect in it shall not affect its sufficiency with respect to other parties hereto.

(b)              
Adjustments in Securities Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution
payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly
or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and
prior to the Closing, each reference in any Transaction Document to a number of Securities or a price per Security shall be deemed
to be amended to appropriately account for such event. The Company shall give to each Purchaser notice of any such event described
hereinabove within one (1) business day of its occurrence, or of any notice given or announcement in respect thereof.

(c)               
Independent Nature of Purchaser’s Obligations and Rights. The obligations of each Purchaser under this Agreement
are several and not joint with the obligations of each other Purchaser, and no Purchaser shall be responsible in any way for the
performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein or in any Transaction Document,
and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchaser as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as
a group with respect to such obligations or the transactions contemplated by this Agreement or any other Transaction Document.
Each Purchaser acknowledges that no other Purchaser will be acting as agent of such Purchaser in enforcing its rights under this
Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights
arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any
Proceeding for such purpose. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for
the convenience of the Company and not because it was required or requested to do so by any Purchaser.

(d)              
Governing Law; Jurisdiction; Jury Trial; Etc. This Agreement shall be governed by, and construed in accordance with,
the laws of the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any manner permitted by law. Each party hereby irrevocably waives any right it may have,
and agrees not to request, a jury trial for the adjudication of any dispute hereunder or in connection with or arising out of this
Agreement or any transaction contemplated hereby. If either party shall commence a proceeding to enforce any provisions of
this Agreement, then the prevailing party in such proceeding shall be reimbursed by the other party for its attorney’s fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such proceeding.

(e)               
Amendments and Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in
a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding or having the right to acquire
66 2/3% of the Securities at the time of such amendment (which amendment shall be binding on all Purchasers or, in the case of
a waiver, by the party against whom enforcement of any such waiver is sought; provided, that any amendment, waiver modification
or supplement of this Agreement that modifies the Investment Amount of, or number of Securities to be acquired by, any Purchaser
may be effected only pursuant to a written instrument signed by the Company and such Purchaser. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall be
offered or paid to any Purchaser to amend or consent to a waiver or modification of any provision of any Transaction Document unless
the same consideration is also offered to all Purchasers who then hold Securities.

(f)               
Entire Agreement. This Agreement supersedes all other prior oral or written agreements among the parties hereto and
Persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced
herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically
set forth herein or therein, none of the parties hereto makes any representation, warranty, covenant or undertaking with respect
to such matters.

(g)              
Successors and Assigns. This Agreement binds and benefits the parties and their respective permitted successors and
assigns. This Section 9(g) does not address, directly or indirectly, whether a party may assign its rights or delegate its
performance under this Agreement.

(h)              
No Assignment; No Delegation. No party may assign any of its rights under this Agreement, except with the prior written
consent of the other parties, provided a Purchaser may assign without consent its rights to purchase Securities to an affiliate
or any Person that shares a common discretionary investment adviser with the Purchaser. All assignments of rights are prohibited
under this Agreement, whether they are voluntary or involuntary, by merger (regardless of whether the party is the surviving or
disappearing entity), consolidation, dissolution, operation of law, or any other manner. For purposes of this Section 9(h),
a “change of control” is deemed an assignment of rights. No party may delegate any performance under this Agreement.
Any purported assignment of rights or delegation of performance in violation of this Section 9(h) is void.

(i)                
Execution. This Agreement may be executed in any number of counterparts, each of which when so executed shall be
deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that any signature
is delivered by facsimile transmission, or by email delivery of a “.pdf” format data file, such signature shall create
a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force
and effect as if such facsimile or digital signature were the original thereof.

(j)                
Severability. If any provision of this Agreement is determined to be invalid, illegal or unenforceable, the remaining
provisions of this Agreement remain in full force, if the essential terms and conditions of this Agreement for each party remain
valid, binding, and enforceable.

(k)              
No Construction Against the Drafter. Each party has participated in negotiating and drafting this Agreement, so if
an ambiguity or question of intent or interpretation arises, this Agreement is to be construed as if the parties had drafted it
jointly, as opposed to being construed against a party because it was responsible for drafting one or more provisions of this Agreement.

(l)                
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.

(m)            
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person,
except that (i) the Placement Agent is an intended third party beneficiary of (A) the Purchasers’ representations and warranties
set forth in Section 2 and (B) the Company’s representations and warranties set forth in Section 3 and (ii) the Placement
Agent shall be entitled to rely upon the legal opinion identified in Section 6(f) pursuant to the reliance letter referenced in
Section 6(f).

[Signature Pages Follow]

    	 

    	 

    

IN WITNESS WHEREOF,
the parties hereto have caused their respective signature page to this Securities Purchase Agreement to be duly executed as of
the date first written above.

 

	GUIDED THERAPEUTICS, INC.
	 
	 
	By:_/s/ Mark L. Faupel___________________
	Name: Mark L. Faupel, Ph.D.
	Title: President and Chief Executive Officer
	 
	 
	 
	 
	 
	 
	 
	 
	 

 

    	 

    	 

    

NAME OF PURCHASER:

Cranshire Capital Master Fund, Ltd. ___ _____

By: /s/ Keith A. Goodman

Name: Keith A. Goodman

Title: Authorized Signatory

Aggregate Purchase
Price (“Investment Amount”):

$200,000.24___________

Number of Preferred Shares to be Acquired:

200___________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

294,118________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

 

    	 

    	 

    

NAME OF PURCHASER:

Equitec Specialists, LLC ___ _____

By: /s/ Keith A. Goodman

Name: Keith A. Goodman

Title: Authorized Signatory

Aggregate Purchase
Price (“Investment Amount”):

$50,000.40 __________

Number of Preferred Shares to be Acquired:

50_ __________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

73,530_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

    	 

    	 

    

NAME OF PURCHASER:

Ronald Hart ___ _____

By: /s/ Ronald Hart

Name: Ronald Hart

Title:

Aggregate Purchase
Price (“Investment Amount”):

$ 25,000.00 __________

Number of Preferred Shares to be Acquired:

25____________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

36,765_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

    	 

    	 

    

NAME OF PURCHASER:

Capital Ventures International by Heights Capital Management its Authorized Agent ___ _____

By: /s/ Martin Kobinger 

Name: Martin Kobinger

Title: Investment Manager

Aggregate Purchase
Price (“Investment Amount”):

$300,000 __________

Number of Preferred Shares to be Acquired:

300______________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

441,176_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

    	 

    	 

    

NAME OF PURCHASER:

John E. Imhoff ___ _____

By: /s/ John E. Imhoff

Name: John E. Imhoff

Title:

Aggregate Purchase
Price (“Investment Amount”):

$ 500,000.00 __________

Number of Preferred Shares to be Acquired:

500____________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

735,294_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

    	 

    	 

    

NAME OF PURCHASER:

Lynne H. Imhoff ___ _____

By: /s/ Lynne H. Imhoff

Name: Lynne H. Imhoff

Title:

Aggregate Purchase
Price (“Investment Amount”):

$ 100,000.00 __________

Number of Preferred Shares to be Acquired:

100____________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

147,059_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

 

    	 

    	 

    

NAME OF PURCHASER:

Alpha Capital Anstalt ___ _____

By: /s/ Konrad Ackermann

Name: Konrad Ackermann

Title: Director

Aggregate Purchase
Price (“Investment Amount”):

$ 500,000.00 __________

Number of Preferred Shares to be Acquired:

500____________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

735,294_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

    	 

    	 

    

NAME OF PURCHASER:

Dolores Maloof ___ _____

By: /s/ Dolores Maloof

Name: Dolores Maloof

Title:

Aggregate Purchase
Price (“Investment Amount”):

$ 102,000.00 __________

Number of Preferred Shares to be Acquired:

102____________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

150,000_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

 

    	 

    	 

    

NAME OF PURCHASER:

David B. Musket ___ _____

By: /s/ David B. Musket

Name: David B. Musket

Title:

Aggregate Purchase
Price (“Investment Amount”):

$ 500,000.00 __________

Number of Preferred Shares to be Acquired:

500 ___________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

735,294_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

    	 

    	 

    

NAME OF PURCHASER:

Promed Partners, L.P. ___ _____

By: /s/ David B. Musket

Name: David B. Musket

Title: General Partner

Aggregate Purchase
Price (“Investment Amount”):

$ 150,000.00 __________

Number of Preferred Shares to be Acquired:

150 ___________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

220,588_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: __________________________

    	 

    	 

    

NAME OF PURCHASER:

The Whittemore Collection, Ltd. ___ _____

By: /s/ Stephen J. Suddney

Name: Stephen J. Suddney

Title: Vice President

Aggregate Purchase
Price (“Investment Amount”):

$ 100,000.00 __________

Number of Preferred Shares to be Acquired:

100 ___________________

Warrants to be Acquired (number of Warrant Shares, to be split into two equal tranches):

147,059_________________

Tax ID No.: ____________________

Address for Notice/Residency
of Purchaser:

__________________________________

__________________________________

__________________________________

Telephone No.: _______________________

Facsimile No.: ________________________

E-mail Address: ________________________

 

Attention: _______________________

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: ______________________

 

Attention: ______________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]